Raxtozinameran

6 trials 1 recruiting JAnti-infectives

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

1 Recruiting

4 Completed trials

6 Sponsors

9 Countries

Phase III

Phase II/III

Phase III/IV

Phase IV

Phase III: 1 Phase II/III: 1 Phase III/IV: 1 Phase IV: 3

Indications tested

Sponsors using this IMP

Finnish Institute For Health And Welfare 1 GlaxoSmithKline Biologicals 1 Hipra Scientific S.L. 1 Klinikum rechts der Isar der TU Muenchen AöR 1 Sciensano 1 Universitair Medisch Centrum Groningen 1

All trials

6 total

LONGITUDINAL FOLLOW-UP OF SARS-COV-2 IMMUNITY IN IMMUNOCOMPROMISED POPULATIONS IN BELGIUM (COVICO) A non-commercial multicenter academic pro… Pending

2024-518098-33-01 Phase IV 1 country Sciensano
Anti-viral action against Type 1 diabetes autoimmunity GPPAD-05-AVAnT1A Recruiting

2023-507348-35-00 Phase IV 6 countries Klinikum rechts der Isar der TU Muenchen AöR
A study on the immune response and safety of a vaccine against respiratory syncytial virus (RSV) when given alone and together with a vaccin… Ended

2023-510196-59-00 Phase III 3 countries GlaxoSmithKline Biologicals
A Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to assess the safety and immunog… Ended

2023-508458-25-00 Phase II/III 1 country Hipra Scientific S.L.
PREPARE-iVAC Ended

2023-503894-39-00 Phase III/IV 1 country Universitair Medisch Centrum Groningen
COVID-19 vaccine immunology Ended

2024-517357-27-00 Phase IV 1 country Finnish Institute For Health And Welfare

Showing 1–6 of 6 trials

← All drugs A–Z